The authors found that the glycaemic benefits of tirzepatide in T2D resulted from concurrent improvements in key components of the diabetes pathophysiology, namely β-cell function, insulin sensitivity and glucagon secretion [60]. Here, INS is linked to type 2 diabetes mellitus.